• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Darzalex Faspro May Improve Progression, Survival in Smoldering Multiple Myeloma

by | Dec 9, 2024 | Uncategorized

Source: CureToday articles The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma. Read More

Daratumumab superior to active monitoring for high-risk smoldering multiple myeloma

by | Dec 8, 2024 | Uncategorized

SAN DIEGO — Daratumumab monotherapy significantly delayed progression of high-risk smoldering multiple myeloma to active multiple myeloma compared with active monitoring, according to results of the randomized phase 3 AQUILA study.Daratumumab (Darzalex, Janssen)...

D-VRd May Improve Minimal Residual Disease Responses in Multiple Myeloma

by | Dec 8, 2024 | Uncategorized

Source: CureToday articles For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival. Read More

High-fiber diet may slow progression of precursor conditions to multiple myeloma

by | Dec 7, 2024 | Uncategorized

SAN DIEGO — A high-fiber plant-based diet may delay progression of certain precursor conditions to multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.The intervention also improved biomarkers of the disease, results of the...

Blenrep Combo Accepted for FDA Review in R/R Multiple Myeloma

by | Dec 3, 2024 | Uncategorized

Source: CureToday articles The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed or refractory multiple myeloma. Read More

Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma

by | Nov 18, 2024 | Uncategorized

Source: CureToday articles Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference. Read More
« Older Entries
Next Entries »

Recent Content

  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Real-World Outcomes Show Efficacy, Safety of Ciltacabtagene Autoleucel in Relapsed, Refractory Multiple Myeloma
  • Equecabtagene Autoleucel Shows Efficacy, Safety in Treatment of Patients With Heavily Pretreated Multiple Myeloma
  • Anitocabtagene autoleucel exhibits durable efficacy in high-risk advanced multiple myeloma
  • Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
  • Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
  • ASH 2024: Cilta-Cel Achieves Sustained MRD Negativity in Patients With Multiple Myeloma
  • Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapies
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT